Time of Metastatic Disease Presentation and Volume of Disease are Prognostic for Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

BACKGROUND: Currently, there is no universally accepted prognostic classification for patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT). Subgroup analyses demonstrated that pts with low volume (LV), per CHAARTED trial definition,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Prostate
Main Authors: Francini, Edoardo, Gray, Kathryn P., Xie, Wanling, Shaw, Grace K., Valença, Loana, Bernard, Brandon, Albiges, Laurence, Harshman, Lauren C., Kantoff, Philip W., Taplin, Mary-Ellen, Sweeney, Cristopher J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6171350/
https://ncbi.nlm.nih.gov/pubmed/29707790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.23645
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados